Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

76613

	registered interest
	date	01/07/2014
	answering body	Wales Office
	answering dept id	28
	answering dept short name	Wales
	answering dept sort name	Wales
	hansard heading	NATO
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Wales, what assessment he has made of the potential benefits of the 2014 NATO Summit to Wales.
	tabling member constituency	Plymouth, Sutton and Devonport
	tabling member printed	Oliver Colvile
	uin	904690
	answer	answer is ministerial correction date of answer 09/07/2014 answer text <p> </p><p>The NATO Summit – hosted in the City of Newport – will be an important event to showcase Wales to an international audience. This will be the largest gathering of World Leaders the UK will have ever hosted. It will highlight and help further strengthen the economic opportunities for the country.</p><p> </p> answering member constituency Clwyd West answering member printed Mr David Jones question first answered 09/07/2014 13:06:25 answering member 1502 label Biography information for Mr David Jones
	tabling member	4022 label Biography information for Oliver Colvile

100599

	registered interest
	date	20/10/2014
	answering body	Department for Transport
	answering dept id	27
	answering dept short name	Transport
	answering dept sort name	Transport
	hansard heading	Roads: Repairs and Maintenance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Transport, what financial assistance he is providing to local authorities to repair potholes.
	tabling member constituency	Plymouth, Sutton and Devonport
	tabling member printed	Oliver Colvile
	uin	905617
	answer	answer is ministerial correction date of answer 23/10/2014 answer text <p>The Government recognises that potholes are a menace for all road users. We are providing over £10 billion for local highways maintenance between 2010 and 2021, including £168 million through the Pothole Fund announced in the March 2014 Budget.</p><p> </p><p> </p> answering member constituency Scarborough and Whitby answering member printed Mr Robert Goodwill question first answered 23/10/2014 10:43:48 answering member 1562 label Biography information for Sir Robert Goodwill
	tabling member	4022 label Biography information for Oliver Colvile

76924

	registered interest
	date	07/07/2014
	answering body	Department for Transport
	answering dept id	27
	answering dept short name	Transport
	answering dept sort name	Transport
	hansard heading	Railways: Plymouth
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Transport, what progress his Department has made on a second railway line to connect Plymouth with London and the Midlands.
	tabling member constituency	Plymouth, Sutton and Devonport
	tabling member printed	Oliver Colvile
	uin	904748
	answer	answer is ministerial correction date of answer 10/07/2014 answer text <p> </p><p>It is for the south west local authorities and the local enterprise partnership to continue to stress the importance of additional rail route to connect Plymouth to London and the Midlands.</p><p> </p><p> </p><p> </p><p>However, I would like to emphasise that a long term resilient rail route to Plymouth and far South West is a priority for this Government. Network Rail is reviewing measures of improvement in a number of key locations on the Western Route.</p><p> </p><p> </p><p> </p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 10/07/2014 13:59:31 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4022 label Biography information for Oliver Colvile

64834

	registered interest
	date	30/06/2014
	answering body	Speaker's Committee on the Electoral Commission
	answering dept id	36
	answering dept short name	Speaker's Committee on the Electoral Commission
	answering dept sort name	Speaker's Committee on the Electoral Commission
	hansard heading	Polling Stations: Schools
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the hon. Member for South West Devon, representing the Speaker's Committee on the Electoral Commission, if the Electoral Commission will take steps to ensure that schools are only used as polling stations as a last resort, in order to minimise disruption to pupils' education.
	tabling member constituency	Plymouth, Sutton and Devonport
	tabling member printed	Oliver Colvile
	uin	203008
	answer	answer is ministerial correction date of answer 09/07/2014 answer text <p> </p><p>The Electoral Commission informs me that the Returning Officer (RO) at an election is responsible for deciding which polling stations will be used for the poll. The Electoral Commission issues guidance to ROs to support them in reaching decisions on the selection of venues for polling stations. Electoral legislation provides that ROs can require a room in publicly-funded schools for use as a polling station and can use these rooms free of charge.</p><p> </p><p> </p><p> </p> answering member constituency South West Devon answering member printed Mr Gary Streeter question first answered 09/07/2014 13:11:07 answering member 234 label Biography information for Sir Gary Streeter previous answer version 7940 answering member constituency South West Devon answering member printed Mr Gary Streeter answering member 234 label Biography information for Sir Gary Streeter
	tabling member	4022 label Biography information for Oliver Colvile

49356

	registered interest
	date	30/04/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what his policy is on the licensing of e-cigarettes.
	tabling member constituency	Plymouth, Sutton and Devonport
	tabling member printed	Oliver Colvile
	uin	197421
	answer	answer is ministerial correction date of answer 06/05/2014 answer text <p /> <p /> <p>On 14 March 2014, European Union member states formally adopted the revised Tobacco Products Directive, including the provisions for regulation of electronic cigarettes. Article 18 of the Directive will subject electronic cigarettes to consumer products legislation, with specific additional regulatory requirements unless they fall under the definition of a medicinal product.</p><p> </p><p>The Medicines and Healthcare products Regulatory Agency is continuing to focus on regulating medicinal nicotine containing products, including electronic cigarettes, to enable licensed products that meet appropriate standards of safety, quality and efficacy to be available. Marketing authorisation applications have been submitted and interest in licensing continues.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 197422 question first answered 06/05/2014 12:00:00 answering member 3918 label Biography information for Jane Ellison
	tabling member	4022 label Biography information for Oliver Colvile

49357

	registered interest
	date	30/04/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether his Department has given consideration to licensing e-cigarettes as medicines.
	tabling member constituency	Plymouth, Sutton and Devonport
	tabling member printed	Oliver Colvile
	uin	197422
	answer	answer is ministerial correction date of answer 06/05/2014 answer text <p /> <p /> <p>On 14 March 2014, European Union member states formally adopted the revised Tobacco Products Directive, including the provisions for regulation of electronic cigarettes. Article 18 of the Directive will subject electronic cigarettes to consumer products legislation, with specific additional regulatory requirements unless they fall under the definition of a medicinal product.</p><p> </p><p>The Medicines and Healthcare products Regulatory Agency is continuing to focus on regulating medicinal nicotine containing products, including electronic cigarettes, to enable licensed products that meet appropriate standards of safety, quality and efficacy to be available. Marketing authorisation applications have been submitted and interest in licensing continues.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 197421 question first answered 06/05/2014 12:00:00 answering member 3918 label Biography information for Jane Ellison
	tabling member	4022 label Biography information for Oliver Colvile

49358

	registered interest
	date	30/04/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if his Department will put restrictions in place to prevent the promotion of e-cigarettes to people under the age of 16 years.
	tabling member constituency	Plymouth, Sutton and Devonport
	tabling member printed	Oliver Colvile
	uin	197423
	answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>The revised Tobacco Products Directive (Directive 2014/40/EU) will prohibit the advertising of e-cigarettes marketed as consumer electronic products where there is a cross-border dimension, for example television, radio, newspapers and magazines. The Department will consult on the transposition of the Directive into United Kingdom law and seek views on the need for domestic provisions on advertising.</p><p> </p><p>It was not possible to achieve age of sale controls through the revised Directive so the Government has already moved quickly to take regulation-making powers for Ministers in England and Wales to prohibit the sale of e-cigarettes to under-18s, through the Children and Families Act. In England, we plan to bring this new law into effect within the current Parliament.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 06/05/2014 12:00:00 answering member 3918 label Biography information for Jane Ellison
	tabling member	4022 label Biography information for Oliver Colvile

58513

	registered interest
	date	05/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prostate Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the changes in the level of access to prostate cancer treatments since 2010.
	tabling member constituency	Plymouth, Sutton and Devonport
	tabling member printed	Oliver Colvile
	uin	199302
	answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199303 199304 question first answered 10/06/2014 15:28:08 answering member 3918 label Biography information for Jane Ellison
	tabling member	4022 label Biography information for Oliver Colvile

58515

	registered interest
	date	05/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prostate Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what treatments for prostate cancer are routinely funded by NHS England.
	tabling member constituency	Plymouth, Sutton and Devonport
	tabling member printed	Oliver Colvile
	uin	199303
	answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199304 question first answered 10/06/2014 15:28:10 answering member 3918 label Biography information for Jane Ellison
	tabling member	4022 label Biography information for Oliver Colvile

58516

	registered interest
	date	05/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prostate Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment his Department has made of outcomes for men with advanced prostate cancer.
	tabling member constituency	Plymouth, Sutton and Devonport
	tabling member printed	Oliver Colvile
	uin	199304
	answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199303 question first answered 10/06/2014 15:28:11 answering member 3918 label Biography information for Jane Ellison
	tabling member	4022 label Biography information for Oliver Colvile